PROCEPT BioRobotics (NASDAQ:PRCT) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious

Simply Wall StMay 21 13:07 ET

PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference

SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solu

PROCEPT BioRobotics May 13 00:00 ET

Alight, Novavax, and More Stocks See Action From Activist Investors

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from May 2 through May 8, 2024. Source: VerityData

Barron'sMay 11 02:17 ET

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)

TipRanksMay 8 00:10 ET

Unveiling 4 Analyst Insights On PROCEPT BioRobotics

4 analysts have shared their evaluations of PROCEPT BioRobotics (NASDAQ:PRCT) during the recent three months, expressing a mix of bullish and bearish perspectives.In the table below, you'll find a sum

BenzingaMay 6 13:00 ET

PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen

PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen

Dow JonesMay 6 12:11 ET